Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPFP | 49.32 | 0.12 | +0.25% |
| JPMorgan Managed Futures Plus ETF (JPFP) | |||
| TXUG | 25.98 | 0.06 | +0.23% |
| Thornburg International Growth Fund ETF (TXUG) | |||
| BYLD | 21.75 | -0.09 | -0.41% |
| iShares Yield Optimized Bond ETF (BYLD) | |||
| IBHL | 24.31 | -0.10 | -0.42% |
| iShares iBonds 2032 Term High Yield and Income ETF (IBHL) | |||
| FENY | 36.59 | -0.30 | -0.81% |
| Fidelity MSCI Energy Index ETF (FENY) | |||
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.
| Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
|---|---|---|---|---|
| ARQT | 100% | +2.37% | ||
| XNCR - ARQT | 48% Loosely correlated | +3.30% | ||
| PTGX - ARQT | 46% Loosely correlated | +0.62% | ||
| PTCT - ARQT | 44% Loosely correlated | +11.89% | ||
| TRDA - ARQT | 42% Loosely correlated | -7.63% | ||
| TGTX - ARQT | 42% Loosely correlated | +1.33% | ||
More | ||||
a company, which engages in the development and commercialization of treatments for dermatological diseases.
Industry Biotechnology
ARQT's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for ARQT moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 28 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 58 of 69 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ARQT broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.403) is normal, around the industry mean (3.051). ARQT's P/E Ratio (154.773) is considerably higher than the industry average of (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (439.647).